Trial reportBMC complementary medicine and therapies2025
Exploring the therapeutic impact of Salvia officinalis on lipid and oxidative stress markers in patients with polycystic ovary syndrome - a randomized placebo-controlled clinical trial.
Trial report in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protective role of aqueousFrontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSalvia.officinalis (S. officinalis), is recognized for its antihyperlipidemic, metabolism-regulating, and antioxidant properties in diabetic and hyperlipidemic disorders. This study examining its effects on lipid and oxidative stress (OS) markers in patients with Polycystic Ovary Syndrome (PCOS), thereby substantiating its role in managing metabolic disorders.
methodsIn this randomized placebo-controlled trial was performed in gynecology clinics affiliated to Iran University of Medical Sciences. Accordingly, 70 Iranian married women aged 15-40 years with newly diagnosed PCOS were included. They were randomized to receive either 330 mg of S. officinalis extract or placebo daily for eight weeks. The study outcomes included lipid profile and OS markers.
resultsThe study found a significantly lower triglyceride levels and malondialdehyde after eight weeks of S. officinalis extract intake compared to placebo. Also, the mean change of triglyceride, high-density lipoprotein cholesterol, malondialdehyde, and total antioxidant capacity were statistically significant in intervention group.
conclusionThe study demonstrates that S. officinalis extract can significantly reduce triglyceride levels and OS in patients with PCOS, suggesting its potential as an adjunctive natural therapy for managing metabolic and oxidative imbalances associated with this condition. While the extract did not significantly alter other lipid profile markers, the observed improvements highlight the therapeutic promise of S. officinalis. These findings support further investigation into the clinical applications S. officinalis for PCOS and its potential benefits for metabolic health.
trial registrationIRCT201504146917N2 on 2015-10-03 (registered while recruiting).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.